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Abstract
Background: The aim of this retrospective study was to assess the results concerning the regional
and systemic toxicity and complications in 242 chemo-hyperthermal treatments (HILPs) for lower
limb melanoma.
Patients and methods: 60 HILPs (G-A) were performed with mild HT plus L-PAM (10 mg/lt) ±
D-actimomycin; 74 HILPs (G-B) with true HT (40–41.8°C) plus L-PAM (10 mg/lt) ± D-act; 108
HILPs (G-C) with true HT plus L-PAM (10 mg/lt) ± D-act plus L-PAM (5 mg/lt) additional bolus.
Results: Limb toxicity was very low in G-A and in G-B; increasing toxicity (grade III = 37%) in G-
C; no grade IV statistical difference was registered in all three groups, with percentage values
among 1.6% and 2.7%. Systemic toxicity showed itself only in the haemopoietic parameters. No
differences were registered in G-B vs G-A group. In G-C vs G-B a significative increase of systemic
toxicity was seen in grade 3 (p < 0.05). Postoperative complications were acceptable. Local and
systemic side-effects were transient; no permanent neurological limb deficit was registered. The
postoperative mortality was recorded in 3/182 HILPs (1.6%) of the G-B and G-C groups.
Conclusion: These data suggested that the technical implementations reduced the occurrence
and the severity of the side effects and complications. The essential requirement for HILP is the
quality assurance of the procedures. Although higher regional and systemic toxicity were observed
in the G-C group caused by L-PAM additional bolus, the safeness of the procedures under the true
hyperthermal regimen and the time increase of the high L-PAM concentration have assured the
treatment reliability along with the increased clinical efficacy expectations of the treatments.
Background
The isolated limb perfusion (ILP) by an extracorporeal cir-
culation is a surgical procedure that has proven to be an
effective option for the treatment of the stage III
melanoma. The present ILP represents a wide treatment
modality in regional metastatic cutaneous melanoma in
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combination with or without the regional lymphadenec-
tomy. The rationale for ILP is based on the assumption
that exposing tumours to a high concentration of citotoxic
agent(s) it will increase the cell kill and can treat both
macroscopic and microscopic regional disease by deliver-
ing the therapeutic effect to the whole limb, and accom-
plishing the change that the diffused micrometastases can
be attacked in order to eliminate the residual sub-clinical
disease [1-3]. The evidence of the disease progression is
pointed-out in around 85.5% of the patients at high risk
(thicker than 1.5 mm) with primary melanoma of the
extremities developed within the locoregional distribu-
tion of the primary tumour [4]. The melphalan (L-PAM)
is the most employed drug in the clinical practice. The
standard of L-PAM dosage is 10 mg/lt of lower limb vol-
ume and can be administered in combination with other
drugs. However, the modality and time of drug adminis-
tration during the perfusion are performed in different
ways from centre to centre in relation with other parame-
ters, types and combination of citotoxic agents. During
the past four decades the perfusional procedure has been
refined and modified by adding heat in order to increase
the tumour cell kill [5,6]. The use of hyperthermia (HT) as
an antineoplastic agent is based on biological and experi-
mental evidence [7-10]. A Different hyperthermal treat-
ment planning has been adopted in many clinical
experiences, e.g. HT levels in the range of 38 to 40°C
(mild-HT) [11-13] or high temperature in the range of 40
to 42°C (borderline true HT) [14-18].
For more than twenty years, our institution has performed
242 ILPs for lower limb melanoma with L-PAM in combi-
nation with hyperthermia. The surgical technique for vas-
cular isolation, the treatment regimens and the support
apparatus technologies were modified with time, on the
basis of our experimental evidence and of the obtained
clinical results.
This paper analyses the results obtained with our hyper-
thermal ILP (HILP) procedures, in terms of toxicity and
morbility, performed in three groups of patients, with dif-
ferent treatment schedules.
Patients and methods
Eligibility criteria and basic procedural guidelines
Planning the same loco-regional treatments, only patients
with melanoma of the lower limb were selected for this
study. Regardless of the disease stage all patients who
underwent HILP were included. A computer assisted data-
base, allowed the patients selection according to the loca-
tion of the tumour and the treatment variables. Disease
was staged according to the M.D. Anderson Classification
System [19]. The inclusion criteria calculated, the age
between 18–80 years, the performance status grade 0–1
(WHO scale), the absence of vascular diseases and other
malignancies. A written informed consent was obtained.
In all patients the vascular isolation was performed at iliac
level or femoral level for the second perfusion. The HILP
eligibility was indicated in the multiple transit metastasis
and also in only one in-transit metastasis showed up
within 30–60 days after the surgical excision of the pri-
mary melanoma subsequently suggesting to perform
HILP. Since this recurrence pattern represents multifocal
involvement of the extremity's lymphatic system, the local
excision of these in-transit lesions is frequently followed
by a rapid recurrence [20]. The iliac and the obturator
lymph-node dissection was performed during the vascular
iliac isolation. The femoral lymph-node dissection and/or
the excision of the primary tumour were performed in the
same surgery procedure after HILP, when required.
The various problems and proposed solutions about the
main surgical aspects regarding the vascular isolation, the
fundamental criteria for an efficient heat supply and accu-
rate and stable temperature control and measurement,
have all been presented in previous works [2,18,21-23].
The review of our extensive experience was described in a
recent report [24]. Before 2001, the systemic leakage was
measured with RIHSA-125 based on a posteriori quantita-
tive determination. [25,26] We have recently adopted the
tasonermina-TNFα (Beromun®) protocol for real time
continuous leakage monitoring during HILP, using a
mobile gamma-probe and a 99mTC-Albumine micro-col-
loid (Albumoscint®) according to the Beromun ILP Proce-
dure Guide [27].
To evaluate the post-operative regional acute toxicity
effects and/or complications, a daily clinical examination
of the limb is performed. Clinical observations and bio-
humoral data were collected for 30 post-operative days in
order to assess the adverse effects. The regional toxicity is
graded according to Wieberdink et al. (table 1) [19]. Dur-
ing the follow-up, the occurrence of long-term sequelae
were valued. The systemic toxicity was measured by WHO
criteria [28]. For the results analysis (non parametric sta-
tistical test), a P-value <0.05 was considered significant.
Changes in clinical practice with time
242 HILP in 213 patients (29 second perfusions) were
performed in our institution from January 1984 until
December 2007. The HILP treatments included three
groups (table 2) with reference to the hyperthermic regi-
men (hyperthermic degree of limb tissue during the active
phase of the treatment), the melphalan dosage with or
without D-actinomycin and the period when HILP was
carried out.Journal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
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G-A Group
HILPs (n = 60) were performed with L-PAM (10 mg/lt of
limb volume) under mild hyperthermic (38–40°C) con-
ditions (1984–1989).
G-B Group
HILPs (n = 74) were performed with L-PAM (10 mg/lt)
under borderline true hyperthermic (40–41.8°C) condi-
tions (1988–1994).
G-C Group
HILPs (n = 108) were performed with double L-PAM
bolus (10 mg/lt and additional bolus of 5 mg/lt) under
borderline true hyperthermic (40–41.8°C) conditions
(1990–2007).
In the G-A Group, the administering of L-PAM was per-
formed when the limb temperatures reached range 38–
39°C; in the G-B Group at 39°C and in the G-C Group,
when the limb temperatures reached 39°C in 53/108
HILPs and 40°C in 55/108 HILPs. In all treatments the
standard dose of L-PAM 10 mg/l was administered as a
single bolus in the arterial line. In the G-C group, the addi-
tional L-PAM bolus was administered 30 minutes after the
first L-PAM bolus. The active phase of treatment was
maintained for 60 minutes; only in 31 HILPs (according
to WHO trial n°17 protocol) [29] the active phase was
maintained for 90 minutes. D-actinomycin (1 mg stand-
ard dosage) was administered before L-PAM only in 10
HILPs (16.7%) in the G-A group; 15 (20.2%) in the G-B;
43 HILPs (39.8%) in the G-C.
HILP Procedure
The technique and methodology used for HILP, were pre-
viously described. [2,23,30]. Hereinafter, we report the
currently procedure that we have adopted, resulted from
the outcome of our clinical experience in borderline true
HT treatments with a particular reference to the adopted
advices in preventing the regional and systemic adverse
effects. In the lower limb HILP, we perform the deep vas-
cular isolation at iliac level after the external iliac and
obturator lymphnodes dissection. Under systemic hepari-
zation (150 UI/Kg b.w.) the iliac vessels are cannulated
and the extracorporeal circuit is inserted. Optimal vascu-
lar blockage is obtained by the temporary clamping of the
internal iliac artery, the common iliac vein and by the
legation of the inferior epigastric and the circumflex ves-
sels. For the femoral cannulation, the technical details
about this vascular approach were previously reported [2].
The cannulas, usually 16F for the artery and 24F for the
vein, guarantee high perfusate flow rate in order to reach
the appointed hyperthermal temperature of the limb tis-
Table 1: Grading of acute limb toxicity according to Wieberdink et al.
Grade I No subjective or objective evidence of reaction
Grade II Slight erythema and or oedema
Grade III Considerable erythema and/or oedema with some blistering; slightly disturbed motility
Grade IV Extensive epidermolysis and/or obvious damage to the deep tissue, causing definite functional disturbances; threatening or 
manifest compartiment syndromes
Grade V Severe reaction which may necessitate amputation
Table 2: Patients' characteristics – protocol schedules.
HILP Group G-A G-B G-C
HT schedule MILD TRUE TRUE
H I L P  =  n 6 07 41 0 8
Period 1984–1989 1988–1994 1990–2007
Gender: M/F 16/44 29/45 29/79
Age: median yrs (range) 55.1 (24–76) 52 (20–70) 60.6 (30–78)
Mean body weigh: kg (range) 68.3 (45/97) 69.8 (50–96) 70 (45–138)
Mean limb volume: lt (range) 10.4 (7.5–14) 11.1 (8.2–16) 10.3 (7.5–20.5)
Stage I-II: HILP = n (%) 34 (56.7) 59 (79.8) 4 (3.7)
Stage III-IV: HILP = n (%) 26 (43.3) 15 (20.2) 104 (96.3)
HT grade 38–40°C 40–41.8°C 40–41.8°C
L-PAM mg/lt limb vol 10 10 10
mg for 1 lt of prime 10 10 10
mg/lt limb vol - - 5 (add. bolus)
Mean L-PAM mg (range) 114.1 (85–150) 122.9 (92–195) 163 (120–240)
D-act. 1 mg: HILP = n (%) 10 (16.6) 15 (20.2) 43 (39.8)
First HILP = n (%) 55 (91.7) 70 (94.6) 88 (81.5)
Second HILP = n (%) 5 (8.3) 4 (5.4) 20 (18.5)Journal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
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sue. The surface isolation for iliac and femoral perfusion
is obtained by the constriction of the belt fastened to a
pair of (modified) Steinmann nails inserted into the sub-
cutaneous layer of the lower abdominal wall (abdominal
tourniquet) [26].
The monitoring of the limb temperature is secured by six
probes inserted in the cutaneous, subcutaneous and mus-
cular tissues: three probes are positioned every time at the
middle third of the thigh and the others three at the mid-
dle of the leg. The limb is wrapped by a warm water circu-
lation blanket that in association with the heated
perfused, allows to obtain homogeneous tissue tempera-
tures throughout the limb and to reach the operative ther-
mal range without the need of heating the perfusate over
42°C at the oxygenator. Consequently, strict and manda-
tory requirements arise in the borderline true HT and a
temperature close to the physiological tolerability limit
(41.5–41.8°C at the arterial cannula) is required. This
safety limits make an accurate and real-time control of the
temperature inside the various tissues and compartments
of the limb. We have lately used a new device (Meditherm
II, Gaymar, AB Medica) of the external heat source in
which the water blanket temperature is set at 41°C for the
whole time of the surgical procedure and during the per-
fusional treatment until the washing-out starts. Care is
taken to guarantee the thermal limb isolation in order to
reduce the heat loss [30].
During the time of the surgical vascular isolation, the
extracorporeal circuit is primed with plasma expander
(1000 ml with sodium heparin 500 UI) and circulation is
started with a short circuit between the arterial and venous
lines. The prime pre-heating is thus obtained (40°C). The
prime volume expressed in liters, is added to the total L-
PAM dosage. Before the administering of L-PAM, the sys-
temic leakage is always monitored.
When the extracorporeal circulation starts, the adminis-
tration of L-PAM is performed when the limb temperature
has reached 40°C and the active phase starts. D-actinomy-
cin when employed, is administered ten minutes before L-
PAM. The chemo-hyperthermal phase is maintained for
60 minutes at the temperature range of 41–41.8°C. The
additional bolus (5 mg/lt) is administered 30 minutes
after the first L-PAM standard dosage, during the active
phase, in order to maintain a high concentration for a
longer time. The perfusate flow is maintained at 600–800
ml/min during the transitory thermal phase of the prime
heating. Typically, when the limb temperature reaches
40°C, the flow rate may be reduced up to 300–400 ml/
min before the drug administering. This action allows to
contain the systemic leakage and at the same time check-
ing that the various temperatures remain substantially
constant in time. Afterwards, the perfusate flow rate is
again risen step by step so that the temperature will rise to
41.5–41.8°C. Figs. 1 and 2 show the temperatures/time
and leakage/time typical profiles of the borderline true
HILP with double L-PAM bolus.
At the end of the active phase the washing-out is per-
formed. The perfusate is drained out and at the same time
the circuit is rinsed with 6000 ml of electrolyte solution at
38°C and consecutively 1000 ml of hydroxyethilic starch
(Amidolite®) solution. After the washing-out completion,
the venous line is clamped and 1000 ml of hydroxyethilic
starch are perfused into the arterial line for protection
against oedema and platelet aggregation. The tourniquet
is released and the vascular cannulas are removed. A tubu-
lar drainage is placed in the retroperitoneal seat for 3–4
days. When the femoral lymph-node dissection is per-
formed, two vacuum-scaled Redon drainages are placed at
the femoral seat for 8–10 days. No fasciotomies are per-
formed. Heparinization is not reversed and patients are
maintained under heparinic control during the postoper-
ative course until they have recovered full mobility.
Results
A total of 242 HILPs (213 pts) were selected for this study:
168 women (69.4%) and 74 men (30.6%) with a mean
age of 56.6 years (range 20–78). The main purpose of this
study was to validate the feasibility and security of more
intensive perfusional treatments with hyperthermal regi-
men, close to the upper limit of physiological tolerability.
In this paper the toxicity and the complications checked in
the three HILP-groups performed in three periods of our
clinical experience were analysed and compared.
Two essential requirements were reached: (1) the thermic
profile of the soft tissues of the entire limb was always
maintained during the active phase of the treatment [24]
at a constant temperature between 40 and 41.8°C; (2) the
systemic leakage data obtained from the two used proce-
dures, have guaranteed values at 5 minutes constantly
below the threshold value of 5% [26].
In the HILPs collected rate, the disease stage was reported
in table 3: in G-A stage I (48.4%) was as part of the EORTC
Trial n°15 [31] and in G-B stage I (78.3%) was as part of
the WHO Melanoma Programme Trial n°17 [29]. In stage
IV the HILPs were palliative treatments.
The grading of the acute limb toxicity in the single HILPs
group is reported in table 4. The grade II and III reactions
were observed with no different rate in G-A and G-B;
whereas the G-C group presented a higher toxic reaction
(grade III in the 37% of HILPs).
In the groups G-B and G-C (182 HILPs) in which the bor-
derline true hyperthermia was used, the regional acuteJournal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
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toxicity was observed with grade II in 121 HILPs (66.4%);
III in 50 (27.5%); and grade IV in 4 (2.1%).
Although the little number of second perfusions, the
regional toxicity occurred with more severe compared to
the first HILP. G-A: grade II in all HILPs; G-B: 75% vs 83%
grade II and 25% vs 13% grade III; G-C: 50% vs 57% grade
II, 45% vs 35% grade III and 5% vs 2% grade IV.
The clinical parameters observed in the grade II reaction
were transient (7–10 days), the erythema and oedema
slide were often not combined. In HILPs with grade III
more intense erythema and/or oedema occurred, espe-
cially when a regional node dissection was also per-
formed. Some superficial and confined blistering seldom
occurred with the restitution ad integrum within 5–8 days.
Only one case (grade III G-C) was associated to severe
pancitopenia with acute respiratory distress. The func-
tional morbidity or nerve effects occurred in one HILP
(Trial 17-G-B group) with grade II toxicity and with per-
sisting cutaneous limb hyperaesthesia. In one HILP-grade
III (G-C) it was observed a continuous and permanent dif-
fused pain to the entire limb and no response to the phar-
macological treatment. The Grade IV reaction was in two
cases: in one HILP G-B (Trial n°17) the reaction was
observed with wide areas of deep burn in the cutaneous
and subcutaneous tissue of the thigh and leg, and plastic
surgery was needed; the next one (G-C) suffered a serious
blistering of the thigh from transitory to moderate reduc-
tion of the motility function. Two other IV grade cases'
reaction with neuropathy respectively occurred in G-B and
G-C; each case developed a multi-organ failure (see table
5).
The acute systemic toxicity was evaluated according to the
WHO criteria [32]: blood analysis was performed when
D.A. – ILP (28.03.07) – Typical temperature profile during lower limb perfusion with L-PAM bolus (10 mg/lt) plus additional  bolus (5 mg/lt) Figure 1
D.A. – ILP (28.03.07) – Typical temperature profile during lower limb perfusion with L-PAM bolus (10 mg/lt) 
plus additional bolus (5 mg/lt).
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required according to the clinical conditions, at least every
three days for the first post-operative period (10 days) and
to the completion of 30 days. Table 6 reports the most fre-
quent haematological parameters that in HILP treatments
are liable to be changed. The analysis of the collected data
pointed out that in G-A and G-B the most significant hae-
matological data do not differ. In particular, in both
groups the RBC and Hb parameters in main grade 2 and 3
of toxicity were collected. The WBC and PLT parameters in
main 2 and 4 grade. Whereas a remarkable rate of haema-
tological parameters tested in the G-C treatment were col-
lected in main grades 2, 3 and 4. These remarks showed a
transitory increase of the haematological and medullar
toxicity with a homogeneous supply in the high-grades.
No major toxicity was recorded from the analysis of the
hepatic and renal function in the three groups. The sys-
temic toxicity in all the treatment groups was typically
observed within the five post-operative days, followed by
early normalization (5–7 days). In some cases the need to
administer some red blood cell units during early post-
operative days.
The clinical observation, reported in table 5, evaluated the
side-effects and the complications attributable to the com-
plex treatment, correlated with the surgical techniques
combined with the citotoxic therapy, The loco-regional
complications were more frequent in G-B and G-C
groups. Following the drains, after 8–10 days the develop-
ment of a lymphocele was observed in four HILPs of G-A
group (6.6%); in G-B: 9.4% and in G-C: 17.5%. This com-
plication was treated with punctures or repeated place-
ment of a suction drain during the follow-up.
Retroperitoneal bleeding in the size of the iliac vascular
isolation occurred in four HILPs and required the wound
revision. A homolateral deep venous thrombosis was
recorded in five HILPs with complete recovery through a
standard medical therapy. An acute respiratory distress
was observed in two HILPs, they were transient and
showed a favourable clinical evolution by reducing the
blood dilution after the washing-out. One bilateral pleu-
ral effusion and a pulmonary microembolism were seen
in two HIILPs (G-B – Trial n°17); both situations were
D.A. – ILP (28.03.07) – Continuous leakage monitoring by 99mTc- Albumoscint and by manual gamma probe (leakage/time  profile) Figure 2
D.A. – ILP (28.03.07) – Continuous leakage monitoring by 99mTc- Albumoscint and by manual gamma probe 
(leakage/time profile).
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Table 3: HILPs (%) collected according to stage disease
HILP Group Stage
I II III IV
G-A (n = 60) 48.4 8.3 43.3 -
G-B (n = 74) 78.3 1.3 20.4 -
G-C (n = 108) 0.9 2.7 92.7 3.7
Table 4: Regional toxicity grade according to HILP group (%)
HILP Group Grade (acc. to Wieberdink et al)
II II I I I V V
G-A (n = 60) 1.6 85.2 11.6 1.6 -
G-B (n = 74) 2.7 81.1 13.5 2.7 -
G-C (n = 108) 4.6 56.6* 37* 1.8 -
* G-B vs G-C (p < 0.005)Journal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
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resolved with a sub-intensive care within 7–10 days. Post-
operative mortality occurred in 3/242 HILPs (1.2%). One
case (G-B) with MOF caused by a compartmental syn-
drome, died on the6th post-operative day. The other one
(G-C) died 10 days after HILP, suffering from severe and
early bone marrow followed by a septic shock. Severe
ARDS in one HILP (G-C) with grade III reaction caused
death after 20 days.
Discussion
Higher-temperature treatments are associated in the pub-
lished results with greater efficacy but also with major
toxic effects especially when the contribution of the asso-
ciated cytostatic drugs is considered [28,33]. In our insti-
tution, over the years, progresses in technologies and
methodology have improved the results with regard to
side-effects through the carrying out of safer and more
acceptable procedures in spite of the use of the borderline
true hyperthermia. In addition, previous clinical results
reported in our pilot study [34] demonstrated that border-
line hyperthermia with an increase of L-PAM concentra-
tion in the advanced lower limb melanoma (stage III) has
improved the locoregional disease-free interval and the
overall survival rate.
In this report the analysis of the acute regional toxicity
data in HILPs-GA (mild HT) allows to remark that only a
moderate toxicity was observed with grades II/III (85/
11%). The Wieberdink grades of the HILPs-GB (true HT)
compared with the data of GA group with the same stand-
ard L-PAM dosage, confirm that the use of true hyperther-
mia up to 41–41.8°C do not cause a higher regional
toxicity. In our experience with true hyperthermal treat-
ments, acceptable regional toxic reactions can be achieved
on condition that the high value of temperature, close to
the maximum physiologically tolerable limit, should
never be higher than 42°C at both levels of the limb tissue
and of the perfusate during a long treatment time
[24,35,36]. In addition, the essential requirement was a
critical control of the temperature through the limb-cir-
cuit system which intrinsically implies uniformity in
space and time [23]. Comparing the Wieberdink grade
between G-C (true HT plus double L-PAM bolus and G-B
(true HT with standard L-PAM dose) pointed out a higher
increase of grade III vs grade II in G-C group. These data
show that the increase of toxic reactions is due to the high
L-PAM administered concentration. Nevertheless, in both
groups (true HT) compared with G-A, an increase of the
grade IV toxicity was not registered, and the toxic reactions
in the HILPs group (true HT) were included in II-III Wie-
berdink grades. These remarks, especially for grade III
were valued, in our experience, as a moderate toxicity con-
sidering that the clinical events were often single and/or
transitory.
The acute systemic toxicity regarding the haematologic
parameters has pointed out a progressive increase towards
higher toxic grades (3–4) in G-C vs G-B group, whereas no
statistical difference was matched between G-B and G-A
groups. These results induce us to make the following
remarks: (i) the vascular isolation technique use in our
procedure has not influenced significantly the drug sys-
temic leakage, on condition that continuous and strict
leakage monitoring is adopted; (ii) in the treatments with
true-HT (74 HILPs) the increase of the systemic toxicity
has not occurred in comparison to mild-HT treatments;
(iii) a higher toxicity found in G-C vs G-B group with the
same HT conditions, must be attributed to the high L-
Table 5: Acute systemic toxicity (HILP %)
HILP Group G-A (n = 60) G-B (n = 74) G-C (n = 108)
G r a d e 01234 0 1 2 340 1 2 3 4
RBC 3,3 26,8 56,6 13,3 0,0 2,7 21,6 54,0 17,6 4,1* 0,9 15,7 50,0 27,8￿ 5,6
H b 3 , 31 6 , 7 6 3 , 3 1 5 , 01 , 4 2 , 7 1 6 , 25 0 , 02 5 , 75 , 4 2 , 8 8 , 33 9 , 9 ￿ 41,6 7,4
WBC 18,3 11,7 31,7 25,0 13,3 36,5* 10,9 12,1* 24,3 16,2 10,2￿ 10,2 20,4 26,8 32,4￿
PLT 61,7 21,7 10,0 5,0 1,6 71,6 9,5* 8,1 4,0 6,8* 23,1￿ 31,7￿ 12,9 12,0￿ 20,3￿
ALT/AST 30,0 48,3 15,0 5,0 1,7 48,7* 33,8 13,5 4,0 0,0 57,4 29,6 7,4￿ 2,8 2,8
CPK 15,0 30,0 28,4 18,3 8,3 29,7* 21,7 27,0 13,5 8,1 37,9 24,1 24,1 8,4 5,5
Creatin 76,8 20,0 1,6 1,6 0,0 87,9 9,5* 1,3 1,3 0,0 91,8 5,5 0,9 0,9 0,9
*G-B vs G-A statistical difference is significant; ￿ G-C vs G-B statistical difference is significant
Table 6: Post-operative regional and systemic complications in 
HILP groups.
HILP Group G-A n (%) G-B n (%) G-C n (%)
Lymphocele 4 (6.6) 7 (9.4) 19 (17.5)
Bleeding necessitating surgery - 1(1.3) 3(2.7)
Deep venous thrombosis - 2(2.6) 3(2.7)
Pain 1(1.6) 1(1.3) 1(0.9)
Peripheral nerve palsy - 1(1.3) 1(0.9)
ARDS 1(1.6) - 1(0.9)
Pleural effusion - 1(1.3) -
Pulmonary microembolism - 1(1.3) -
Death (MOF or ARDS) - 1(1.3) 2(1,8)Journal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
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PAM concentration (additional bolus); (iiii) high L-PAM
concentration over along time is liable to the damage of
the haematopoietic function, whereas does not directly
interfere with the hepatic and renal functions.
The postoperative regional and systemic complications in
all HILP groups have not showed a statistical difference;
however, a trend on a moderate increase was matched in
G-C group. These remarks were seen to be in relation with
the higher median age of the patients with possible
comorbidities and/or advanced disease (stage IIIAB)
necessitating more invasive combined surgery (i.e. simul-
taneous regional lymph-node dissection) as occurred in
G-C group.
In our opinion according to Knorr et al [37] the overall
side-effects and complications data found with these HILP
procedures are acceptable in the face of the more intensive
perfusional treatments. We have reason to believe that the
analysis of our clinical data involving borderline hyper-
thermia with or without increase of the L-PAM concentra-
tion, will confirm the benefit of our innovative
perfusional procedure by improving the local control of
the disease and possibly the survival rate.
Competing interests
The Authors have no direct nor indirect financial and no-
financial interests in the procedures and techniques pre-
sented in this paper.
Authors' contributions
All the Authors have made substantial contributions to
conception, design, acquisition data, analysis and inter-
pretation of data. MP was involved in the conception,
design, analysis and interpretation of data. RG was
involved in the design, acquisition of data, analysis and
interpretation of data. MM and EMM were involved in the
acquisition of data and the analysis of data. PB was
involved in the conception, design, analysis and interpre-
tation of data.
Acknowledgements
Bulgarelli G., Statistician – Statistical Office, University of Florence. This 
work was partially supported by Research Budgets (ex-60%) of the Univer-
sity of Florence.
References
1. Krementz ET, Muchmore JH, Carter RD, Sutherland CM: Regional
chemotherapy for melanoma of the limbs.  Contrib Oncol 1988,
29:247-260.
2. Pace M: Optimization of the vascular isolation in isolated
regional perfusion of the limbs.  Reg Cancer Treat 1990, 3:90-97.
3. Noorda EM, Takkenberg B, Vrouenraets BC, Nieweg OE, van Geel
BN, Eggermont AM, Hart GA, Kroon BB: Isolated limb perfusion
prolongs the limb recurrence-free interval after several epi-
sodes of excisional surgery for locoregional recurrent
melanoma.  Ann Surg Oncol 2004, 11(5):491-499.
4. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF: Recurrent malig-
nant melanoma: the identification of prognostic factors to
predict survival.  Ann Plast Surg 1992, 28(1):45-49.
5. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson
RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A: Selective
heat sensitivity of cancer cells.  Cancer 1967, 20:1351-1381.
6. Stehlin JS: Hyperthermic perfusion with chemotherapy for
cancers of the extremities.  Surg Gynecol Obstet 1969,
129:305-308.
7. Bhuyan BK: Kinetics of cell kill by hyperthermia.  Cancer Res
1979, 39:2277-2284.
8. Hahn GM, Shiu EC: Effect of pH and elevated temperature on
the cytotoxicity of some chemotherapeutic agents on Chi-
nese hamster cells in vitro.  Cancer Res 1983, 43:5789-5791.
9. Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck
LE, Gibbs FA Jr, et al.: Biological and clinical aspects of hyper-
thermia in cancer therapy.  Am J Clin Oncol 1988, 11(3):368-380.
10. Zaffaroni N, Villa R, Daidone MG, Vaglini M, Santinami M, Silvestrini
R: Antitumor activity of hyperthermia alone or in combina-
tion with cisplatin and melphalan in primary cultures of
human malignant melanoma.  Int J Cell Cloning 1989, 7:385-394.
11. Skene AI, Bulman AS, Williams TR, Meirion TJ, Westburg G: Hyper-
thermic isolated perfusion with melphalan in the treatment
of advanced malignant melanoma of the lower limb.  Br J Surg
1990, 77:765-767.
12. Vrouenraets BC, Veld GJ, Nieweg OE, van Slooten GW, van Dongen
JA, Kroon BBR: Long-term functional morbidity after mild
hyperthermic isolated limb perfusion with melphalan.  Eur J
Surg Oncol 1999, 25(Suppl 5):503-508.
13. Storm FK, Morton DL: Value of therapeutic hyperthermic limb
perfusion in advanced recurrent melanoma of the lower
extremity.  Am J Surg 1985, 150:32-35.
14. Stehlin JS Jr, Giovanella BC, De Ipolyi PD, Muenz LR, Anderson RF:
Results of hyperthermic perfusion for melanoma of the
extremities.  Surg Gynecol Obstet 1975, 140(3):339-348.
15. Ghussen F, Kruger I, Groth W, Stutzer H: The role of regional
hyperthermic cytostatic perfusion in the treatment of
extremity melanoma.  Cancer 1988, 61:654-659.
16. Pace M, Galli A, Sussi S, Bellacci A: True hyperthermia in isolated
regional perfusion for the treatment of limb melanoma.  Reg
Cancer Treat 1991, 4:35.
17. Hafström L, Rudenstam CM, Blomquist E, Ingvar C, Jönsson PE, Lager-
löf B, Lindholm C, Ringborg U, Westman G, Ostrup L: Regional
hyperthermic perfusion with melphalan after surgery for
recurrent malignant melanoma of the extremities. Swedish
Melanoma Study Group.  J Clin Oncol 1991, 9(12):2091-2094.
18. Meyer T, Gohl J, Haas C, Hohenberger W: Hyperthermic isolated
limb perfusion-23 years experience and improvement of
results by modification of technique.  Onkologie 1998,
21:198-202.
19. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis
GAA: Dosimetry in isolated perfusion of the limbs by assess-
ment of perfused tissue volume and grading of toxic tissue
reactions.  Eur J Cancer Clinic Oncol 1982, 18:905-910.
20. Balch C: Cutaneous Melanoma.  3rd edition. ST. Luis, MO: Quality
Medical Publishing; 1998. 
21. Pace M, Filomena A, Galli A: Thermal induction and tempera-
ture control in the hiperthermic antiblastic regional per-
fusion with extra-corporeal circulation. In Consensus on
Hyperthermia for the 1990s.  In Clinical Practice in Cancer Treat-
ment Edited by: Bicher HI et al. New York:. Plenum Press;
1990:399-403. 
22. Pace M, Millanta L, Bellacci A, Galli A, Lazzerini S: Heat admistra-
tion temperature monitoring and control in hyperthermic
antiblastic perfusion of the limbs.  Reg Cancer Treat 1993,
4:207-212.
23. Pace M, Millanta L, Galli A, Bellacci A: Closely controlled, highly
reproducible and uniform temperature distribution in
hyperthermal isolated limb perfusion.  Reg Cancer Treat 1994,
2:94-98.
24. Pace M, Millanta L, Polignano M, Gattai R, Macera Mascitelli E: Opti-
mal procedure for thermal delivery in hyperthermic/chemo-
therapeutic treatments in the isolated perfusion of the the
limbs.  J Exp Clin Cancer Res 2005, 24(1):35-42.
25. Gattai R, Macera Mascitelli M, Millanta L, Polignano M, Bini M, Ignesti
A, et al.: Computerization and electronic integration in thePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2008, 27:67 http://www.jeccr.com/content/27/1/67
Page 9 of 9
(page number not for citation purposes)
optimization of biomedical system for the hyperthermic ant-
iblastic perfusion in extracorporeal circulation.  By-Pass 2003,
15(Suppl 1):2043-2046.
26. Pace M, Millanta L, Gattai R, Matteini M, Vaggelli L, Macera Mascitelli
E, Bechi P: Key factors for best control of the systemic leakage
during hyperthermic isolated limb perfusion (HILP) in ECC.
A critical synthesis of our experience.  J Exp Clin Cancer Res 2007,
26:433-442.
27. Leakage monitoring: Beromun ILP Procedure Guide Boehringer Ingel-
heim Pharma KG; 1999:11-13. 
28. Kroon BBR, Klase JM, van Geel AN, Eggermont AMM: Application
of hyperthermia in regional isolated perfusion for melanoma
of the limbs.  Reg Cancer Treat 1992, 4:223-226.
29. Evaluation of efficacy of adjuvant hyperthermic isolation
perfusion in stage I high risk (thickness ≥ 1.5 mm) cutaneous
melanoma of lower limbs.  WHO Melanoma Programme 17.1991 .
30. Pace M, Millanta L, Bellacci M, Galli A, Lazzerini S: Heat administra-
tion temperature monitoring and control in hyperthermic –
antibalstic perfusion of the limbs.  Reg Cancer Treat 1992,
4:207-212.
31. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Göhl J, Egger-
mont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ: Prophy-
lactic isolated limb perfusion for localized, high-risk limb
melanoma: results of a multicenter randomized phase III
trial. European Organization for Research and Treatment of
Cancer Malignant Melanoma Cooperative Group Protocol 1
the World Health Organization Melanoma Program Trial
15, and the North American Perfusion Group Southwest
Oncology Group-8593.  J Clin Oncol 1998, 16(9):2906-2912.
32. Miller AB, Hoogstratem B, Staquet M: Reporting results of cancer
treatment.  Cancer 1981, 47:207-214.
33. Noorda EM, Vrouenraets BC, Nieweg OE, Klaase JM, Zee J van der,
Kroon BBR: Long-term results of a double perfusion schedule
using high dose hyperthermia and melphalan sequentially in
extensive melanoma of the lower limb.  Melanoma Research
2003, 13:395-399.
34. Pace M, Galli A, Bellacci A: True hyperthermia plus double mel-
phalan bolus in the isolated perfusion for stage III lower limb
melanoma.  A pilot study Reg Cancer Treat 1996, 9:1-7.
35. Pace M, Galli A, Bellacci A: Local and systemic toxicity in 'bor-
derline true' hyperthermic isolated perfusion for lower limb
melanoma.  Melanoma Research 1995, 5:371-376.
36. Lazzerini S, Millanta L, Olmi R, Pace M: An analysis of heat supply
and temperature distribution in isolated hyperthermic per-
fusion of the limbs.  Phys Med 1991, 7:135-143.
37. Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W: Hyperther-
mic isolated limb perfusion (HILP) in malignant melanoma.
Experience with 101 patients.  Eur J Surg Oncol 2006, 32:224-227.